Determination of Isepamicin in Human Plasma by HPLC with Fluorescence Detection after Derivatization Using 6-Aminoquinolyl-Nhydroxysuccinimidyl-carbamate
at 250 nm for excitation and 395 nm for emission wavelength. The column was YMC-Pack Pro C 18 AS-302 column (YMC, Tokyo, Japan, 150 mmϫ4.6 mm i.d., 5 mm particle size) and was maintained at 40°C. A guard column Symmetry C 18 (Waters, Milford, U.S.A., 20 mmϫ3.9 mm i.d., 5 mm particle size) was attached before the analytical column. The mobile phase was 20 mM KH 2 PO 4 containing 8 mM triethylamine (pH 7.0)/acetonitrile (78/22, v/v) and was pumped at a flow-rate of 1 ml/min.
Assay Validation Precision and accuracy were examined as follows. Stock solution of ISP was prepared in ionexchanged water at a concentration of 1 mg/ml. This stock solution was diluted with ion-exchanged water to obtain the concentrations required for preparation of standard working solutions. The working solutions were diluted with blank human plasma to prepare calibration samples containing 0.5, 1, 5, 10, 50 mg/ml of ISP. These plasma samples were cleaned up as described above and 5 ml of the mixture after derivatization was directly injected into the HPLC. Calibration curves of ISP were prepared by plotting the peak area ratio (P.A.R.) of ISP to AMK against ISP concentration in plasma. Precision and accuracy were expressed as the relative standard deviation (R.S.D.) and the percentage error of nominal versus the measured concentration (R.E.), respectively. The limit of quantification (LOQ) was determined as the lowest concentration in the calibration curve that could be measured with acceptable precision and accuracy. A maximum R.S.D. of 20% and a maximum R.E. of Ϯ20% were allowed. 19) Recoveries were evaluated by comparing peak areas of plasma samples after the clean-up procedure with areas obtained from aliquots of working solutions which were directly derivatized.
Intra-day variability was tested on five different human plasma samples using the same calibration curve. Inter-day variability was tested on five different days and each day a new calibration curve was constructed.
To confirm the stability, spiked plasma samples contained ISP and AMK at 10 mg/ml concentration level, respectively, were subjected to clean-up and derivatization procedure, then injection samples were stored at room temperature (15-25°C) in natural light (below 700 lux, approximately). Stability of ISP and AMK derivatives was evaluated by comparing peak areas, recoveries and P.A.R. after storage for 2 or 7 d with those immediately after derivatization.
Measurement of Other AGs in Human Plasma
Spiked plasma samples contained only ISP, ISP and gentamicin, ISP and tobramycin, ISP and arbekacin at 10 mg/ml concentration level, respectively, were subjected to clean-up and derivatization procedure, then samples were injected into the HPLC. Figure 2 illustrates typical chromatograms obtained from blank human plasma those which had spiked with ISP and AMK. Capacity ratios of ISP and AMK were 9.1 and 8.8, respectively. A good separation of ISP and AMK from remaining endogenous contaminants was achieved using five different human plasma specimens.
RESULTS
A standard curve was constructed for ISP by plotting the peak area ratio of ISP to AMK as a function of the plasma ISP concentrations (0.5, 1, 5, 10, 50 mg/ml). There is an excellent linearity over the range of 0.5-50 mg/ml. The mean equation describing the calibration curve in human plasma was yϭ0.08xϪ0.064 where y is the peak area ratio of ISP against AMK and x is the concentration of ISP, with a mean correlation coefficient of 1.000 (nϭ5).
Recoveries of ISP and AMK after clean-up procedures were evaluated at a concentration of 10 mg/ml. Recoveries of ISP and AMK were 36.1Ϯ6.1% and 17.2Ϯ3.7%, respectively (meanϮS.D., nϭ5).
The intra-and inter-day assay precision and accuracy values are given in Table 1 . The intra-day precision (R.S.D.) varied between 7.5 and 10.8%, and the accuracy (R.E.) was within Ϯ17.5% for all values. The inter-day precision varied between 1.7 and 13.0%, and the accuracy was within Ϯ9.2% for all values. According to this study, the range of quantification for ISP in human plasma was 0.5-50 mg/ml, and the LOQ for ISP in human plasma was 0.5 mg/ml. Table 2 shows the stability of ISP and AMK derivatives at ambient condition. Peak areas of ISP and AMK derivatives after storage for 2 or 7 d tend to increase in comparison with those measured immediately after derivatization, but the difference was not significant. The tendencies were almost same about the recoveries of ISP and AMK after clean-up procedures and P.A.R. of ISP to AMK (Table 2) . Figure 3 illustrates typical chromatograms obtained from human plasma those which had spiked with only ISP, ISP and gentamicin, ISP and tobramycin, ISP and arbekacin. Since capacity ratios of gentamicin, tobramycin and arbekacin were almost equal to that of AMK, a good separation of ISP and these AGs from remaining endogenous contaminants was achieved.
DISCUSSION
Although the assay of aminoglycosides using FPIA techniques is done frequently in many hospital laboratories, FPIA kit for IPS is discontinued in Japan. Instead of FPIA, several HPLC methods for determination of ISP in human plasma using fluorescent derivatizing reagent have been reported, however, the main disadvantage of these methods is that the derivatives are unstable. Therefore, Maloney et al. generated post-column derivatization, 10) which requires further HPLC systems. The method described uses AQC, a new fluorescent derivatizing reagent, the method is simple and more rapid for determination of ISP in human plasma and the validity has been verified.
With pre-column derivatization we found it difficult to separate the ISP peak from interfering peaks. In order to remove contaminants from plasma prior to derivatization, a clean up procedure with dichloromethane was carried out after the protein precipitation by addition of acetonitrile as reported by Peng et al. 8) This step could remove interfering peak caused from contaminants in plasma.
Recoveries of ISP and AMK after clean-up procedure were relatively limited, which may be due to an insufficient amount of AQC. Increasing the amount of the reagent resulted in a larger peak area of the derivative (data not shown). In general, excessive amount of derivatizing reagent should be added to the reaction. However, when potential application for routine therapeutic drug monitoring (TDM) is 1868 Vol. 31, No. 10 Fig. 3 . Typical Chromatograms Obtained from Human Plasma Spiked with (A) Only Isepamicin (10 mg/ml), (B) Isepamicin (10 mg/ml) and Gentamicin (10 mg/ml), (C) Isepamicin (10 mg/ml) and Tobramycin (10 mg/ml) and (D) Isepamicin (10 mg/ml) and Arbekacin (10 mg/ml) considered, the increased expenditure for the reagent would present a serious obstacle. Therapeutic limits in TDM for ISP are lower than 35 mg/ml for peak concentration and lower than 10 mg/ml for trough concentration, respectively. 20) Therefore, the method described is sensitive enough to be applied to routine TDM for ISP.
The disadvantage of methods using typical fluorescent derivatizing reagents is lower stability and possible disturbance by excessive reagents, and AQC was overcome this disadvantage. ISP and AMK derivatives were stable for at least a week at ambient condition. This excellent stability enables simple derivatization using the pre-column method, and gives the good reproducibility of measurement. There were not significant differences between FPIA kits method and AQC derivatization method for ISP detection.
We selected gentamicin, tobramycin and arbekacin as other AGs which were measured at routine TDM and tested the possibility of measurement of these AGs in human plasma. Capacity ratios of other AGs except ISP were almost equal, but only capacity ratio of ISP was larger than those of other AGs. Therefore, simultaneous determination of these AGs may be impossible under the condition as described in Materials and Methods, but if ISP will be used as internal standard, single determination of these AGs except ISP will be possible.
In conclusion, we developed a simple and rapid HPLC method for determination of ISP in human plasma using AQC, a new fluorescent derivatizing reagent. This method could be applied to routine TDM for ISP. AQC could be applicable not only for the derivatization of other AGs, but also other drugs with primary and secondary amino groups.
